1.上海中医药大学附属龙华医院(上海 200032)
2.上海中医药大学(上海 201203)
3.广东省中医院(广东 广州 510120)
尹萌辰,男,博士,主治医师,主要从事中医药治疗骨肿瘤的临床与基础研究工作;
莫文,教授,主任医师,博士研究生导师;E-mail:mw2218@126.com
扫 描 看 全 文
尹萌辰, 许崇卿, 王洪伸, 等. 基于文献计量学及可视化技术的中医药治疗骨肉瘤研究现状及热点分析[J]. 上海中医药杂志, 2021,55(10):4-13.
Mengchen YIN, Chongqing XU, Hongshen WANG, et al. Current status and hotspot analysis of research on traditional Chinese medicine treatment of osteosarcoma based on bibliometrics and visualization techniques[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(10):4-13.
尹萌辰, 许崇卿, 王洪伸, 等. 基于文献计量学及可视化技术的中医药治疗骨肉瘤研究现状及热点分析[J]. 上海中医药杂志, 2021,55(10):4-13. DOI: 10.16305/j.1007-1334.2021.1908080.
Mengchen YIN, Chongqing XU, Hongshen WANG, et al. Current status and hotspot analysis of research on traditional Chinese medicine treatment of osteosarcoma based on bibliometrics and visualization techniques[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(10):4-13. DOI: 10.16305/j.1007-1334.2021.1908080.
目的,2,分析中医药治疗骨肉瘤的研究现状及热点,揭示研究热点的动态变化和发展态势,为中医药治疗骨肉瘤的临床及基础研究提供思路和依据。,方法,2,检索收集中国期刊全文数据库(CNKI)、万方医学网数据库、中国生物医学文献服务系统(SinoMed)等数据库中中医药治疗骨肉瘤的研究文献,检索时间为建库至2019年6月。应用文献计量学方法对研究文献的基本情况(发表时间、发文机构、刊载来源、基金项目等)进行分析描述;应用Citespace软件对研究的热点进行知识图谱描绘及可视化分析,包括文献关键词的共现分析、聚类分析、时间线视图分析和突现分析。,结果,2,①经筛选,最终获得有效文献197篇,其中基础研究文献占比较多,临床研究文献较少。②1988年至2019年中医药治疗骨肉瘤相关文献量总体呈上升趋势,涨势较缓,呈波动上涨。③福建中医药大学(校本部及附属机构)发表中医药治疗骨肉瘤文献最多;总体而言,不同区域之间、不同高校机构之间的合作度相对较小。④相关文献分别刊载在38种来源中,包括期刊和学位论文,刊载来源较为分散。⑤国家自然科学基金对本专题研究的资助最多;有基金资助的文献占比不足40%。⑥发文量排名第一的作者(第一作者)是上海中医药大学附属市中医医院的陈永强;相关学者数量较少、分布较散,不同区域的不同作者之间的合作相对较少。⑦共现分析与聚类分析表明,中医药治疗骨肉瘤的研究热点主要是围绕如何调控骨肉瘤细胞的增殖和凋亡展开,其中姜黄素、片仔癀和蜂毒素的研究最为广泛和深入。⑧时间线视图分析表明,中医药治疗骨肉瘤热点关键词2003年至2019年期间的变化趋势明显,免疫调节可能成为研究的前沿点。⑨突现分析表明,雷公藤红素的突现率最高,从2015年起激增。,结论,2,骨肉瘤的中医药研究取得了一定的成果,但总体研究水平仍处于初级阶段,不同区域之间、不同作者团队之间的学术合作有待加强。目前中医药干预骨肉瘤研究的主流是中药单体的基础研究,而骨肉瘤的中医证候标准研究或许是今后的研究重点方向之一。
Objective,2,To analyze the research status and hotspots of traditional Chinese medicine (TCM) treatment of osteosarcoma and to reveal the dynamic changes and development trend of research hotspots for the purpose of providing ideas and basis for the research of TCM treatment of osteosarcoma.,Methods,2,The research literature on TCM treatment of osteosarcoma in databases such as China National Knowledge Infrastructure (CNKI), Wanfang Database of China Medical Collections, and Chinese biomedical literature service system (SinoMed) was retieved from the date of database’s establishment to June 2019. Bibliometric methods were adopted to analyze and describe the basic information of the research literature (publication time, issuing institution, source of publication, fund projects, etc.). The Citespace software was used to depict and visualize the knowledge map of research hotspots, including co-occurrence analysis, cluster analysis, timeline view analysis and emergence analysis of literature keywords.,Results,2,①After screening, 197 valid articles were finally obtained, among which basic research articles were more than clinical research articles. ②The number of articles related to TCM treatment of osteosarcoma from 1988 to 2019 showed an overall upward trend, with a slow and fluctuating rise. ③Fujian University of Traditional Chinese Medicine (the main campus and affiliated institutions) published the most articles on TCM treatment of osteosarcoma. Generally speaking, there was relatively little cooperation among different regions and different universities and institutions. ④The relevant articles were published in 38 different sources, including journal articles and dissertations respectively, and the sources of publication were relatively scattered. ⑤The National Natural Science Foundation of China (NSFC) has topped the sponsorship, but less than 40% of the articles were funded. ⑥The author (first author) with the highest number of publications was Chen Yongqiang from the Shanghai Municipal Hospital of Traditional Chinese Medicine affiliated to Shanghai University of Traditional Chinese Medicine; the number of related scholars was small and they were scattered, and there was relatively little collaboration among different authors from different regions. ⑦The co-occurrence analysis and cluster analysis showed that the research hotspots of TCM treatment of osteosarcoma mainly focused on how to regulate the proliferation and apoptosis of osteosarcoma cells, and curcumin, Pien Tze Huang, and melittin were the most extensively and deeply studied. ⑧The timeline view analysis showed that the hot keyword change of TCM treatment of osteosarcoma from 2003 to 2019 was significant, and immune regulation may become the frontier research point. ⑨The emergence analysis showed that tripterine had the highest emergence rate, which surged from 2015 onwards.,Conclusions,2,The research on TCM treatment of osteosarcoma has achieved certain progress, but the overall research is still in the primary stage, and the academic cooperation among different regions and different research teams needs to be strengthened. At present, the research mainstream of TCM intervention in osteosarcoma is the research on TCM monomers, while the research on TCM syndrome standardization of osteosarcoma may be one of the key research directions in the future.
骨肉瘤中医治疗中药单体研究热点研究现状文献计量学可视化技术
osteosarcomatraditional Chinese medicine treatmenttraditional Chinese medicine monomersresearch hotspotresearch statusbibliometricsvisualization technique
DAILEY D D, ANFINSEN K P, PFAFF L E, et al. HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors[J]. BMC Vet Res, 2013(9):130.
HEARE T, HENSLEY M A, DELLORFANO S. Bone tumors: osteosarcoma and Ewing’s sarcoma[J]. Curr Opin Pediatr, 2009, 21(3): 365-372.
JAFFE N. Osteosarcoma: review of the past, impact on the future. The American experience[J]. Cancer Treat Res, 2009, 152(1): 239-262.
LINDSEY B A, MARKEL J E, KLEINERMAN E S. Osteosarcoma overview[J]. Rheumatol Ther, 2017, 4(1): 25-43.
BARANSKI Z, BOOIJ T H, KUIJJER M L, et al. MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation[J]. Genes Cancer, 2015, 6(11-12): 503-512.
李德华,刘明轩,李琦. 中医药治疗骨肉瘤研究进展[J]. 江西中医学院学报,2008, 20(4): 98-100.
刘云霞,徐叶峰,李梦芸,等. 清化复肝汤防治骨肉瘤甲氨蝶呤化疗性肝损伤的临床研究[J]. 浙江中医杂志,2017, 52(2): 83-84.
司富春, 丁帅伟. 骨肉瘤中医证型与方药分析研究[J]. 世界中西医结合杂志,2015, 10(7): 903-907.
詹红生,陈东煜,张继伟. 中药提取物诱导骨肉瘤细胞程序性死亡研究进展[J]. 中国中医药信息杂志,2016, 23(2): 127-129.
周尧,张俐. 抑制骨肉瘤Survivin表达的中药研究概况[J]. 中国中医骨伤科杂志,2013, 21(2): 65-67.
尹萌辰,王洪伸,孙懿君,等. 基于网络药理学与分子对接技术的益气散瘀解毒方治疗骨肉瘤的潜在机制分析[J]. 上海中医药杂志,2021, 55(7): 17-24, 28.
曹飞,康小红,曹向军,等. 华蟾酥毒基诱导人骨肉瘤细胞U-2OS凋亡的实验研究[J]. 中医学报,2015, 30(7): 945-947.
曹飞,康小红,王立芳. 华蟾酥毒基对人骨肉瘤细胞U-2OS凋亡的影响及作用机制研究[J]. 中国修复重建外科杂志,2014, 28(3): 349-353.
陈炳艺. 片仔癀通过PI3K/Akt通路抑制人骨肉瘤耐药细胞MG63/ADM增殖的机制研究 [D]. 福州:福建中医药大学,2017.
陈婧,刘云霞,匡唐洪,等. 八珍汤联合大剂量化疗治疗骨肉瘤临床观察[J]. 中华中医药学刊,2015, 33(4): 940-943.
陈婧,刘云霞,姚勇伟,等. 自拟护肝方治疗骨肉瘤大剂量甲氨蝶呤化疗后药物性肝损伤的临床观察[J]. 中国中医药科技,2015, 22(2): 180-181.
陈鹏,林庆宾,刘宇,等. 两种清热解毒中成药对骨肉瘤MG63细胞增殖影响的比较研究[J]. 临床医药文献电子杂志,2017, 4(12): 2316-2318.
陈永强,朱振安,戴克戎,等. 蜂毒素对骨肉瘤细胞系细胞增殖的影响[J]. 上海中医药大学学报,2003, 17(1): 55-57.
陈永强,朱振安,郝永强,等. 蜂毒素诱导骨肉瘤细胞U-2OS凋亡与坏死的实验研究[J]. 中西医结合学报,2004, 2(3): 208-209.
樊强. 蜂毒素抑制人骨肉瘤细胞MG63活力及其作用机制的实验研究[D]. 济南:山东大学,2014.
冯其金,王巨存,王博韬. 中药蜂毒素治疗骨肿瘤研究进展[J]. 解放军医药杂志,2014, 26(6): 91-93.
符芳姿,许振胜. 槲皮素对人骨肉瘤MG-63细胞周期及自噬流的影响[J]. 广州中医药大学学报,2019, 36(6): 885-888.
0
浏览量
521
下载量
0
CSCD
2
CNKI被引量
关联资源
相关文章
相关作者
相关机构